IMMUNOME, INC.Board Appointment Rights • October 12th, 2023 • Immunome Aggregator, LP • Pharmaceutical preparations • Delaware
Reference is hereby made to the subscription agreement, dated as of June 29, 2023 (the “Subscription Agreement”), by and between Immunome, Inc. (the “Company”), and Enavate Sciences, LP (the “Enavate Investor”). This letter agreement (this “Agreement”) is being delivered in connection with the purchase by the Enavate Investor of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and the Enavate Investor’s entry into the Subscription Agreement. Capitalized terms used but not defined herein shall have the meanings set forth in the Subscription Agreement.
